RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raises the price target from $32 to $33.
November 03, 2023 | 5:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on ACADIA Pharmaceuticals and raises the price target from $32 to $33.
The news of RBC Capital maintaining an Outperform rating and raising the price target for ACADIA Pharmaceuticals is likely to have a positive impact on the company's stock in the short term. This is because it signals the analyst's confidence in the company's performance and growth potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100